Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae.
The mutant prevention concentration (MPC) represents a threshold above which the selective proliferation of resistant mutants is expected to occur only rarely. A provisional MPC (MPC(pr)) was defined and measured for five fluoroquinolones with clinical isolates of Streptococcus pneumoniae. Based on their potential for restricting the selection of resistant mutants, the five fluoroquinolones, in descending order, were found to be moxifloxacin > trovafloxacin > gatifloxacin > grepafloxacin > levofloxacin. For several compounds, 90% of about 90 clinical isolates that lacked a known resistance mutation had a value of MPC(pr) that was close to or below the serum levels that could be attained with a dosing regimen recommended by the manufacturers. Since MPC(pr) overestimates MPC, these data identify moxifloxacin and gatifloxacin as good candidates for determining whether MPC(pr) can be used as a guide for choosing and eventually administering fluoroquinolones to significantly reduce the development of resistance.
Blondeau
J M
JM
Departments of Clinical Microbiology, St. Paul's Hospital (Grey Nuns') and Saskatoon District Health, Saskatchewan, Canada. blondeauj@sdh.sk.ca
Zhao
X
X
Hansen
G
G
Drlica
K
K
D000890:Anti-Infective Agents / Q000494:pharmacology*; D004269:DNA, Bacterial / Q000235:genetics / Q000302:isolation & purification; D024841:Fluoroquinolones; D006801:Humans; D008826:Microbial Sensitivity Tests; D009154:Mutation / Q000187:drug effects*; D011008:Pneumococcal Infections / Q000382:microbiology; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013296:Streptococcus pneumoniae / Q000187:drug effects* / Q000235:genetics*
D000890:Anti-Infective Agents; D004269:DNA, Bacterial; D024841:Fluoroquinolones